Probe Reprocessing Market Size, Share & Trends Analysis Report By Probe Classification (Critical, Semi-Critical), By Probe Type (Convex Probes, Linear Probes), By Product, By Method, By End Use, By Region, And Segment Forecast, 2025 - 2030
Scleroderma Therapeutics Market Growth & Trends
The global scleroderma therapeutics market size is expected to reach USD 3.44 billion by 2030, registering a CAGR of 5.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is credited to the availability of various therapies used off-label, such as small molecule therapies including branded, generics, and OTC drugs.
The mix of several indications and drug classes engenders a fragmented market with multiple players. Roche is the dominant company with biologic immunosuppressants, Actemra/RoActemra, Cellcept, and Rituxan contributing majorly to the company’s share. Pfizer and Eli Lilly are the key companies in the market. Over the forecast period, new entrants including Boehringer Ingelheim, Corbus Pharmaceuticals, and Fibrocell will marginally displace the share of established firms in this market.
The on-label market is in the development phase. Supplemental indication approval is one of the most common strategies adopted by market participants. For example, riociguat by Bayer was previously used for PAH and currently, it is under clinical trials for the treatment of SSc-related digital ulcers. There are several other pharmaceutical companies following suit as this strategy favors the pharmaceutical industry in offsetting high development costs and in reaping larger benefits from one molecule already developed and present in the market.
Scleroderma Therapeutics Market Report Highlights
- The immunosuppressors segment accounted for the largest share of 27.4% in 2024, and is likely to maintain the dominance throughout the forecast years
- High preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class supports its dominant market share
- Systemic scleroderma indication segment accounted for the major market share and will expand further due to use of high-priced immunosuppressants
- The U.S. market accounted for 90.6% share of the North America scleroderma therapeutics market in 2024. Expected label expansions and expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs support continual scleroderma therapeutics market growth
- Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Probe classification
- 1.2.2. Probe Type
- 1.2.3. Product Type
- 1.2.4. Method
- 1.2.5. End Use
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Regional outlook
- 2.4. Competitive Insights
- Chapter 3. Probe Reprocessing Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Growing Demand For Ultrasound Procedures
- 3.2.1.2. Rising Incidence of Hospital-Acquired Infections
- 3.2.1.3. Development Of Advanced Products
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Recalls Of Probe Reprocessing Products
- 3.3. Probe Reprocessing Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
- Chapter 4. Probe Reprocessing Market - Segment Analysis, by Probe Classification, 2018 - 2030 (USD Million)
- 4.1. Probe Reprocessing Market: Probe Classification Outlook and Key Takeaways
- 4.2. Probe Reprocessing Market: Probe Classification Movement Analysis
- 4.3. Probe Reprocessing Market Estimates & Forecast, by Probe Classification (USD Million)
- 4.4. Critical
- 4.4.1. Critical Market, 2018 - 2030 (USD Million)
- 4.5. Semi-Critical
- 4.5.1. Semi Critical Market, 2018 - 2030 (USD Million)
- 4.6. Non-Critical
- 4.6.1. Non-critical Market, 2018 - 2030 (USD Million)
- Chapter 5. Probe Reprocessing Market - Segment Analysis, by Probe Type, 2018 - 2030 (USD Million)
- 5.1. Probe Reprocessing Market: Probe Type Outlook and Key Takeaways
- 5.2. Probe Reprocessing Market: Probe Type Movement Analysis
- 5.3. Probe Reprocessing Market Estimates & Forecast, by Probe Type (USD Million)
- 5.4. Convex Probes
- 5.4.1. Convex Probes Market, 2018 - 2030 (USD Million)
- 5.5. Linear Probe (Non-critical)
- 5.5.1. Linear Probe Market, 2018 - 2030 (USD Million)
- 5.6. Transesophageal (TEE) Probe
- 5.6.1. Transesophageal Market, 2018 - 2030 (USD Million)
- 5.7. Phased Array/Cardiac Probe
- 5.7.1. Phased Array/Cardiac Probe Market, 2018 - 2030 (USD Million)
- 5.8. Endocavitary Probe
- 5.8.1. Endocavitary Probe Market, 2018 - 2030 (USD Million)
- 5.9. Others
- 5.9.1. Others Market, 2018 - 2030 (USD Million)
- Chapter 6. Probe Reprocessing Market - Segment Analysis, by Product Type, 2018 - 2030 (USD Million)
- 6.1. Probe Reprocessing Market: Product Type Outlook and Key Takeaways
- 6.2. Probe Reprocessing Market: Product Type Movement Analysis
- 6.3. Probe Reprocessing Market Estimates & Forecast, by Product Type (USD Million)
- 6.4. Instruments
- 6.4.1. Instruments Market, 2018 - 2030 (USD Million)
- 6.4.2. Automated Reprocessors
- 6.4.2.1. Automated Reprocessor Market, 2018 - 2030 (USD Million)
- 6.4.3. UV-C Disinfectors
- 6.4.3.1. UV-C disinfectors Market, 2018 - 2030 (USD Million)
- 6.4.4. Manual Reprocessors/Soaking Stations
- 6.4.4.1. Manual Reprocessors/Soaking Stations Market, 2018 - 2030 (USD Million)
- 6.4.5. Ultrasound Probe Storage Cabinets
- 6.4.5.1. Ultrasound Probe Storage Cabinets Market, 2018 - 2030 (USD Million)
- 6.5. Consumables
- 6.5.1. Consumables Market, 2018 - 2030 (USD Million)
- 6.5.1.1. Formulations
- 6.5.1.1.1. Formulations Market, 2018 - 2030 (USD Million)
- 6.5.1.1.2. Disinfectant Wipes
- 6.5.1.1.2.1. Disinfectant Wipes Market, 2018 - 2030 (USD Million)
- 6.5.1.1.3. Disinfectant Liquids
- 6.5.1.1.3.1. Disinfectant Liquids Market, 2018 - 2030 (USD Million)
- 6.5.1.1.4. Disinfectant Sprays
- 6.5.1.1.4.1. Disinfectant Sprays Market, 2018 - 2030 (USD Million)
- 6.5.1.2. Detergent
- 6.5.1.2.1. Detergent Market, 2018 - 2030 (USD Million)
- 6.5.1.2.2. Enzymatic Detergents
- 6.5.1.2.2.1. Enzymatic Detergents Market, 2018 - 2030 (USD Million)
- 6.5.1.2.3. Non-Enzymatic Detergents
- 6.5.1.2.3.1. Non-Enzymatic Detergents Market, 2018 - 2030 (USD Million)
- 6.6. Service
- 6.6.1. Service Market, 2018 - 2030 (USD Million)
- Chapter 7. Probe Reprocessing Market - Segment Analysis, by Method, 2018 - 2030 (USD Million)
- 7.1. Probe Reprocessing Market: Method Outlook and Key Takeaways
- 7.2. Probe Reprocessing Market: Method Movement Analysis
- 7.3. Probe Reprocessing Market Estimates & Forecast, by Method (USD Million)
- 7.4. Sterilization
- 7.4.1. Sterilization Market, 2018 - 2030 (USD Million)
- 7.5. High-Level Disinfection
- 7.5.1. High-Level Disinfection Market, 2018 - 2030 (USD Million)
- 7.6. Intermediate Level Disinfection
- 7.6.1. Intermediate Level Disinfection Market, 2018 - 2030 (USD Million)
- 7.7. Low-Level Disinfection
- 7.7.1. Low-Level Disinfection Market, 2018 - 2030 (USD Million)
- Chapter 8. Probe Reprocessing Market - Segment Analysis, by End Use, 2018 - 2030 (USD Million)
- 8.1. Probe Reprocessing Market: End Use Outlook and Key Takeaways
- 8.2. Probe Reprocessing Market: End Use Movement Analysis
- 8.3. Probe Reprocessing Market Estimates & Forecast, by End Use (USD Million)
- 8.4. Hospitals and Clinics
- 8.4.1. Hospitals and Clinics Market, 2018 - 2030 (USD Million)
- 8.5. Diagnostics Imaging Centers
- 8.5.1. Diagnostics Imaging Centers Market, 2018 - 2030 (USD Million)
- 8.6. Others
- 8.6.1. Others Market, 2018 - 2030 (USD Million
- Chapter 9. Probe Reprocessing Market: Regional Estimates & Trend Analysis
- 9.1. Regional Dashboard
- 9.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
- 9.3. North America
- 9.3.1. U.S.
- 9.3.1.1. Key country dynamics
- 9.3.1.2. Regulatory framework/ reimbursement structure
- 9.3.1.3. Competitive scenario
- 9.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 9.3.2. Canada
- 9.3.2.1. Key country dynamics
- 9.3.2.2. Regulatory framework/ reimbursement structure
- 9.3.2.3. Competitive scenario
- 9.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 9.3.3. Mexico
- 9.3.3.1. Key country dynamics
- 9.3.3.2. Regulatory framework/ reimbursement structure
- 9.3.3.3. Competitive scenario
- 9.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4. Europe
- 9.4.1. UK
- 9.4.1.1. Key country dynamics
- 9.4.1.2. Regulatory framework/ reimbursement structure
- 9.4.1.3. Competitive scenario
- 9.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.2. Germany
- 9.4.2.1. Key country dynamics
- 9.4.2.2. Regulatory framework/ reimbursement structure
- 9.4.2.3. Competitive scenario
- 9.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.3. France
- 9.4.3.1. Key country dynamics
- 9.4.3.2. Regulatory framework/ reimbursement structure
- 9.4.3.3. Competitive scenario
- 9.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.4. Italy
- 9.4.4.1. Key country dynamics
- 9.4.4.2. Regulatory framework/ reimbursement structure
- 9.4.4.3. Competitive scenario
- 9.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.5. Spain
- 9.4.5.1. Key country dynamics
- 9.4.5.2. Regulatory framework/ reimbursement structure
- 9.4.5.3. Competitive scenario
- 9.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.6. Norway
- 9.4.6.1. Key country dynamics
- 9.4.6.2. Regulatory framework/ reimbursement structure
- 9.4.6.3. Competitive scenario
- 9.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.7. Sweden
- 9.4.7.1. Key country dynamics
- 9.4.7.2. Regulatory framework/ reimbursement structure
- 9.4.7.3. Competitive scenario
- 9.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 9.4.8. Denmark
- 9.4.8.1. Key country dynamics
- 9.4.8.2. Regulatory framework/ reimbursement structure
- 9.4.8.3. Competitive scenario
- 9.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5. Asia Pacific
- 9.5.1. Japan
- 9.5.1.1. Key country dynamics
- 9.5.1.2. Regulatory framework/ reimbursement structure
- 9.5.1.3. Competitive scenario
- 9.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.2. China
- 9.5.2.1. Key country dynamics
- 9.5.2.2. Regulatory framework/ reimbursement structure
- 9.5.2.3. Competitive scenario
- 9.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.3. India
- 9.5.3.1. Key country dynamics
- 9.5.3.2. Regulatory framework/ reimbursement structure
- 9.5.3.3. Competitive scenario
- 9.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.4. Australia
- 9.5.4.1. Key country dynamics
- 9.5.4.2. Regulatory framework/ reimbursement structure
- 9.5.4.3. Competitive scenario
- 9.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.5. South Korea
- 9.5.5.1. Key country dynamics
- 9.5.5.2. Regulatory framework/ reimbursement structure
- 9.5.5.3. Competitive scenario
- 9.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 9.5.6. Thailand
- 9.5.6.1. Key country dynamics
- 9.5.6.2. Regulatory framework/ reimbursement structure
- 9.5.6.3. Competitive scenario
- 9.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 9.6. Latin America
- 9.6.1. Brazil
- 9.6.1.1. Key country dynamics
- 9.6.1.2. Regulatory framework/ reimbursement structure
- 9.6.1.3. Competitive scenario
- 9.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 9.6.2. Argentina
- 9.6.2.1. Key country dynamics
- 9.6.2.2. Regulatory framework/ reimbursement structure
- 9.6.2.3. Competitive scenario
- 9.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 9.7. MEA
- 9.7.1. South Africa
- 9.7.1.1. Key country dynamics
- 9.7.1.2. Regulatory framework/ reimbursement structure
- 9.7.1.3. Competitive scenario
- 9.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 9.7.2. Saudi Arabia
- 9.7.2.1. Key country dynamics
- 9.7.2.2. Regulatory framework/ reimbursement structure
- 9.7.2.3. Competitive scenario
- 9.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 9.7.3. UAE
- 9.7.3.1. Key country dynamics
- 9.7.3.2. Regulatory framework/ reimbursement structure
- 9.7.3.3. Competitive scenario
- 9.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 9.7.4. Kuwait
- 9.7.4.1. Key country dynamics
- 9.7.4.2. Regulatory framework/ reimbursement structure
- 9.7.4.3. Competitive scenario
- 9.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 10. Competitive Landscape
- 10.1. Market Participant Categorization
- 10.2. Recent Developments & Impact Analysis by Key Market Participants
- 10.3. Company Market Share Analysis, 2024
- 10.4. Key Company Profiles
- 10.4.1. Nanosonics
- 10.4.1.1. Company overview
- 10.4.1.2. Financial performance
- 10.4.1.3. Product benchmarking
- 10.4.1.4. Strategic initiatives
- 10.4.2. CIVCO Medical Solutions
- 10.4.2.1. Company overview
- 10.4.2.2. Financial performance
- 10.4.2.3. Product benchmarking
- 10.4.2.4. Strategic initiatives
- 10.4.3. Tristel Plc
- 10.4.3.1. Company overview
- 10.4.3.2. Financial performance
- 10.4.3.3. Product benchmarking
- 10.4.3.4. Strategic initiatives
- 10.4.4. Ecolab
- 10.4.4.1. Company overview
- 10.4.4.2. Financial performance
- 10.4.4.3. Product benchmarking
- 10.4.4.4. Strategic initiatives
- 10.4.5. Germitec
- 10.4.5.1. Company overview
- 10.4.5.2. Financial performance
- 10.4.5.3. Product benchmarking
- 10.4.5.4. Strategic initiatives
- 10.4.6. CS Medical LLC
- 10.4.6.1. Company overview
- 10.4.6.2. Financial performance
- 10.4.6.3. Product benchmarking
- 10.4.6.4. Strategic initiatives
- 10.4.7. ASP (Fortive Corporation)
- 10.4.7.1. Company overview
- 10.4.7.2. Financial performance
- 10.4.7.3. Product benchmarking
- 10.4.7.4. Strategic initiatives
- 10.4.8. Steelco S.p.A.
- 10.4.8.1. Company overview
- 10.4.8.2. Financial performance
- 10.4.8.3. Product benchmarking
- 10.4.8.4. Strategic initiatives
- 10.4.9. Metrex Research, LLC
- 10.4.9.1. Company overview
- 10.4.9.2. Financial performance
- 10.4.9.3. Product benchmarking
- 10.4.9.4. Strategic initiatives
- 10.4.10. STERIS
- 10.4.10.1. Company overview
- 10.4.10.2. Financial performance
- 10.4.10.3. Product benchmarking
- 10.4.10.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook